Technology

This double-attenuated influenza virus vector developed and owned by Capricorn Technologies GmbH (partner of GeminiVax), is safe in humans and can be configured to incorporate epitope cassettes containing CTL, T-helper, and B-cell epitopes from the pathogen of interest. Strongly adjuvanting. Enables effective immunisation via several administration routes.

Unique bioinformatics approach for in-silico definition of CTL and B-cell epitopes and prediction of their relative immunogenic strength.

Artificial marker epitope for vaccine-specific immune response monitoring (no cross-reaction with natural flu infection)ELISA confirmation of effective vaccination.

Synthetic, safety-validated adjuvants to enhance or modulate vaccine-induced immune responses (primarily via regulation of dendritic cell polarization).